Tags: Drug.
Varespladib methyl (also known as A-002 formerly LY333013 and S-3013) is a secretory phospholipase A2 (sPLA2) inhibitor formerly under development by Anthera Pharmaceuticals as a treatment for acute coronary syndrome (ACS). Varespladib methyl is an orally bioavailable prodrug of the molecule varespladib. It is currently under active investigation in a Phase III clinical trial called VISTA-16.
